TQB3019 capsules for adults with advanced malignant tumors — safety and early effects

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 1, open-label, non-randomized, single-arm trial uses a dose-escalation stage followed by a dose-expansion stage to explore TQB3019's safety, tolerability, pharmacokinetics, and preliminary efficacy. Participants receive TQB3019 orally in either single-dose or continuous dosing regimens depending on cohort assignment, with regular monitoring for adverse events, drug levels, and tumor response. Eligible adults have recurrent or refractory advanced malignant tumors with at least one measurable lesion and adequate organ function. The study is conducted across major cancer centers in China to identify tolerated doses and early signals of antitumor activity to inform further development.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects voluntarily joined the study, signed informed consent form, and with good compliance.
* ≥18 years old; Eastern Cooperative Oncology Group (ECOG) physical status: 0-2; at least 3 months expected survival period.
* Clearly diagnosed recurrent / refractory hematological tumors that meet the World Health Organization (WHO) definition;
* At least 1 measurable lesion for efficacy evaluation.
* The function of main organs is normal.
* Female patients of childbearing age should agree to use contraceptive measures during the study period and for at least 6 months after study is stopped; a negative serum pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects; male patients should agree to use contraception during the study period and for at least 6 months after study is stopped.

Exclusion Criteria:

* Patients has had or is currently having other malignant tumors within 3 years. The following two conditions can be included in the group: other malignant tumors treated with a single operation to achieved 5 consecutive years of disease free survival (DFS)s. Cured cervical carcinoma in situ, non-melanoma skin cancer, nasopharyngeal carcinoma and superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)\].
* Subjects with central nervous system aggression (CNS);
* Received allogeneic hematopoietic stem cell transplantation (allo-HSCT) or had active graft-versus-host disease (GVHD) requiring immunosuppressive therapy within 12 months before the first dose;
* Multiple factors that affect the absorption of oral medications (e.g., inability to swallow, chronic diarrhea, and intestinal obstruction);
* Unrelieved toxicity of ≥CTC AE grade 1 due to any previous treatment, excluding alopecia and fatigue;
* Major surgical treatment, open biopsy, and significant traumatic injury were received within 28 days before the start of study treatment.
* The presence of active or uncontrolled primary autoimmune cytopenia, including autoimmune hemolytic anemia (AIHA) and primary immune thrombocytopenia (ITP);
* Patients with evidence or history of bleeding constitution; Or any bleeding event (such as gastrointestinal bleeding) greater than or equal to CTC AE level 3 within 4 weeks before the first medication;
* Subjects had an arteriovenous thrombosis event within 6 months.
* Subjects have history of psychotropic substance abuse and are unable to abstain or have mental disorders;
* Subjects with any severe and/or uncontrolled disease.
* Within 2 weeks before the first treatment, the subjects had received proprietary Chinese medicines with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions;
* Previously received treatment with drugs similar to TQB3019 capsules;
* Uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage (investigator judgment)
* Study treatment related: subjects received live or messenger RNA (mRNA) vaccines within 4 weeks before the first treatment or were scheduled to receive live or mRNA vaccines during the study;
* Participated in clinical trials of other antitumor drugs within 4 weeks before the first treatment;
* According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are considered unsuitable for enrollment for other reasons.

Where it's running

• Cancer Institute & Hospital.Chinese Academy of Medical Sciences
  Beijing, Beijing Municipality, China Recruiting
• Nanfang Hospital of Southern Medical University
  Guangzhou, Guangdong, China Recruiting
• The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
  Zhengzhou, Henan, China Recruiting
• Jiangsu Province Hospital
  Nanjing, Jiangsu, China Recruiting
• The First Affiliated Hospital of Nanchang University
  Nanchang, Jiangxi, China Recruiting
• The First Affiliated Hospital of Xi'an Jiaotong University
  Xi'an, Shaanxi, China Recruiting

Study contacts

• Study coordinator: Zengjun Li, Doctor
• Email: zengjunli@163.com
• Phone: +86-13642138692

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TQB3205 capsules for adults with advanced malignant tumors.

  TQB3205 capsules will be tested for safety, tolerability, and how the drug is processed in the body in adults with advanced malignant tumors.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tianjin, Tianjin Municipality · NCT07482592

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

• TR-002 (Nadofaragene Firadenovec) given by IV for adults with advanced unresectable or metastatic solid tumors and refractory metastatic pancreatic adenocarcinoma

  This Phase 1 trial tests whether weekly intravenous TR-002 is safe and what dose is best for adults with advanced unresectable or metastatic solid tumors or refractory metastatic pancreatic cancer.

  Recruiting Phase 1 University of California, Davis · Sacramento, California · NCT07189195

• Early advance care planning education for young adults with advanced solid tumors or high-grade brain tumors

  This project will test whether short educational tools help adolescents and young adults (diagnosed at 18–39) with advanced solid tumors or high-grade brain tumors start advance care planning earlier.

  Recruiting Mayo Clinic · Scottsdale, Arizona · NCT07174661

• Telephone coaching to help people with advanced cancer and their support person plan for end-of-life care

  This program tests whether two phone coaching sessions help people with advanced cancer and their support person have end-of-life conversations and complete advance directives.

  Recruiting at 3 sites Fred Hutchinson Cancer Center · Everett, Washington and 2 other locations · NCT07141407

• Using siltuximab to prevent severe side effects during cancer treatment

  This study is testing if the drug siltuximab can help prevent severe side effects in cancer patients who are getting immune therapy again.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06470971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.